Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China flag China · Delayed Price · Currency is CNY
29.76
+0.41 (1.40%)
Sep 30, 2026, 3:00 PM CST

SHA:688076 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
892.79913.79571.39749.08399.96591.88
Trading Asset Securities
64116208-43.0187.13
Cash & Short-Term Investments
956.791,030779.39749.08442.98679.01
Cash Growth
24.23%32.13%4.05%69.10%-34.76%353.54%
Accounts Receivable
622.84508.32539.21297.26251.29143.37
Other Receivables
82.6874.9963.293.271.191.05
Receivables
705.52583.31602.5300.53252.48144.41
Inventory
944.5859.52584.04377.17323.48250.82
Prepaid Expenses
-0.09----
Other Current Assets
19.7939.6739.667.9833.5329.86
Total Current Assets
2,6272,5122,0061,4951,0521,104
Property, Plant & Equipment
3,1022,9921,8921,405988.47706.55
Long-Term Investments
270.95234.47215.04117.594.5-
Goodwill
156.34156.34156.34156.34156.34160.92
Other Intangible Assets
200.46154.82108.19112.198.1888.57
Long-Term Deferred Tax Assets
149.98128.2184.3746.6528.1316.63
Long-Term Deferred Charges
367.9347.59203.241.0338.7715.66
Other Long-Term Assets
188.17214.69409.4173.8465.4434.46
Total Assets
7,0686,7405,0743,5472,5222,127

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
284.16319.92159.7141.9387.6172.36
Accrued Expenses
126.13179.66149.1286.1448.4943.99
Short-Term Debt
972.151,0171,044546.02318.7377.27
Current Portion of Long-Term Debt
541.38276.1117.8940.08--
Current Portion of Leases
16.4615.39.795.291.473.64
Current Income Taxes Payable
19.196.0619.3511.475.37-
Current Unearned Revenue
42.3148.1761.218.396.8526.17
Other Current Liabilities
307.66300.84191.83134.0182.851.96
Total Current Liabilities
2,3092,1631,753973.34551.32275.4
Long-Term Debt
1,2731,322445.21286.49--
Long-Term Leases
28.9128.8925.7517.18-2.74
Long-Term Unearned Revenue
151.67156.855.9931.4635.3221.74
Long-Term Deferred Tax Liabilities
8.678.278.6110.1610.774.26
Other Long-Term Liabilities
194.7359.18107.4339.31-14
Total Liabilities
3,9663,7392,3961,358597.41318.14

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
316.05316.05219.78213.18213.18213.18
Additional Paid-In Capital
1,7561,7551,5981,3411,3191,318
Retained Earnings
1,024919.08766.56495.37374.95277.82
Comprehensive Income & Other
-4.25-4.3672.17120.233.332.2
Total Common Equity
3,0912,9862,6562,1701,9101,811
Minority Interest
10.8616.221.9519.0414.66-2.61
Shareholders' Equity
3,1023,0022,6782,1891,9251,809
Total Liabilities & Equity
7,0686,7405,0743,5472,5222,127

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,8322,6601,642895.07320.1983.65
Net Cash (Debt)
-1,875-1,630-863.06-145.98122.79595.36
Net Cash Growth
-----79.38%-
Net Cash Per Share
-5.95-5.20-2.80-0.490.412.21
Filing Date Shares Outstanding
316.05316.05307.69298.46298.46298.46
Total Common Shares Outstanding
316.05316.05307.69298.46298.46298.46
Working Capital
317.16349.12252.82521.43501.15828.71
Book Value Per Share
9.789.458.637.276.406.07
Tangible Book Value
2,7342,6742,3921,9021,6561,562
Tangible Book Value Per Share
8.658.467.776.375.555.23
Buildings
828.21--504.29476.24376.08
Machinery
2,8312,4181,6031,123652.13529
Construction In Progress
442.6692.57339.92185.96180.1134.85